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HEALTH AND MEDICINE

Reducing opioid use disorder and overdose deaths
in the United States: A dynamic modeling analysis
Erin J. Stringfellow1, Tse Yang Lim2, Keith Humphreys3, Catherine DiGennaro1, Celia Stafford4,
Elizabeth Beaulieu1, Jack Homer2,5, Wayne Wakeland6, Benjamin Bearnot7, R. Kathryn McHugh8,
John Kelly9, Lukas Glos10, Sara L. Eggers10, Reza Kazemi10, Mohammad S. Jalali1,2*
Opioid overdose deaths remain a major public health crisis. We used a system dynamics simulation model of
the U.S. opioid-using population age 12 and older to explore the impacts of 11 strategies on the prevalence of
opioid use disorder (OUD) and fatal opioid overdoses from 2022 to 2032. These strategies spanned opioid misuse
and OUD prevention, buprenorphine capacity, recovery support, and overdose harm reduction. By 2032, three
strategies saved the most lives: (i) reducing the risk of opioid overdose involving fentanyl use, which may be
achieved through fentanyl-focused harm reduction services; (ii) increasing naloxone distribution to people who
use opioids; and (iii) recovery support for people in remission, which reduced deaths by reducing OUD. Increasing
buprenorphine providers’ capacity to treat more people decreased fatal overdose, but only in the short term. Our
analysis provides insight into the kinds of multifaceted approaches needed to save lives.

Since 1999, nearly 650,000 Americans have died of an opioid overdose.
More than half of these deaths have occurred since 2016 (1, 2), reflecting a series of sequential and overlapping waves, each deadlier than the
last. These waves have been driven by increasing misuse of prescription
opioids, followed by heroin, and now synthetic opioids such as illicitly
manufactured fentanyl, which dominates illicit opioid markets in many
eastern parts of the United States and is quickly spreading west (3).
Billions of federal dollars have been spent to increase access to
lifesaving naloxone and medications for opioid use disorder (OUD) (4),
and opioid prescribing has dropped considerably (5). Yet, nationally,
fatal opioid overdoses reached an all-time high in 2021 (6). At the
same time, national household surveys indicate that initiation of both
prescription opioids and heroin has steadily fallen over the last several
years, and OUD has declined from its peak in 2015 (7). From a complex
adaptive systems perspective, these ostensibly divergent population-
level trends result from an interacting web of feedback loops. People
who use drugs (PWUD) and national policies that target PWUD
change the nature of the overdose crisis and thus the behavioral and
policy responses that follow. Hence, many aspects of the crisis are
endogenous, meaning they arise as a function of the current and historical state of the system rather than independently of it. Often, policies
do not explicitly account for these endogenous responses, which can
be difficult to anticipate and take years to manifest. Policies that
worked in the past or that work now could become less effective in the
future. Policies that until now have been less effective or infeasible could
become more impactful as trends shift. Consequently, policies can
lead to unintended consequences, including worse-before-better (i.e.,
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worsening effects in the short term with net beneficial effects in the
longer term) or better-before-worse dynamics. When these endogenous responses are identified and accounted for, there is greater potential to develop strategies that will likely lead to qualitative, meaningful
shifts in outcomes and avoid strategies that yield little benefit.
Models that simulate future scenarios under different conditions
are helpful because they account for population health and policy temporal dynamics and thus can identify potential consequences of policy
interventions. Simulation models provide policymakers with an interactive approach to testing the effects of different strategies before
implementation, including synergistic outcomes and unintended consequences (8). Feedback-based simulations use endogenous dynamics
to replicate and explain historical trends and carry these dynamics
forward in model projections (9, 10), thus supporting the analysis of
how policy interventions might interact with these dynamics (11).
Here, we present a model-based analysis of 11 strategies related
to opioid misuse and OUD prevention, buprenorphine capacity, recovery support, and overdose harm reduction and their impacts on
OUD prevalence and fatal opioid overdoses. We use a national-level
simulation model of the opioid crisis, SOURCE (Simulation of Opioid
Use, Response, Consequences, and Effects), developed in collaboration
with the U.S. Food and Drug Administration (FDA) (12). SOURCE
is a compartmental feedback model that simulates the movement of
the U.S. opioid-using population through opioid misuse, OUD, and
remission; treatment with medications for OUD (MOUD); and nonfatal and fatal opioid overdose. SOURCE builds on other opioid-
focused models (13–17). It endogenously reproduces historical trends
from 1999 to 2020 and, where the data support it, includes the
operational detail necessary to compare specific mechanisms.
SOURCE was developed to guide strategic direction by identifying the approaches most likely to lead to qualitative, positive shifts
in trends, and those most likely to yield little return. Thus, SOURCE
is most useful for testing high-level targets for national policies rather
than specific interventions. The most impactful strategies revealed
by model testing do not always correspond to any existing evidence-
based interventions. Thus, SOURCE is well suited for testing hypothetical “what if” questions that encourage thinking beyond the
existing intervention toolset, ideally providing the impetus needed
1 of 14
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of 11 high-level strategies on annual fatal opioid overdoses and OUD
prevalence, cumulative fatal opioid overdoses, and cumulative person-
years of OUD from 2022 to 2032. These strategies fall into four categories: (i) opioid misuse and OUD prevention, (ii) buprenorphine
treatment capacity, (iii) recovery support, and (iv) overdose harm
reduction. Table 1 presents the 11 strategies, their operationalization
in the model (indicated in the numbered rows), and corresponding
intervention or policy examples to guide interpretation. More detail on
each of the strategies tested is available in the “Rationale for and implementation of strategy testing” section in Materials and Methods.
We chose strategies to compare the relative impacts across a
breadth of potential intervention points; the assessment of specific
policies and interventions is outside the scope of this paper. Thus,

to develop such interventions. Model-based findings regarding
high-impact strategies, even if they do not correspond to existing
interventions, provide valuable insight when there are limited resources and it is not feasible to direct energies equally toward all
strategies. We report the impacts of the 11 strategies analyzed and
combinations thereof on the projected annual and cumulative prevalence of OUD and fatal opioid overdose from 2022 to 2032.
RESULTS

Strategy selection and testing
The “Glossary” section in the Supplementary Materials provides definitions for terms used throughout this paper. We assessed the effects

Table 1. Strategies simulated in SOURCE (each changed by 20% in desired direction).
Category
(#) Strategy defined in terms of operational implementation in SOURCE

Intervention or policy example

(↓↑ labels show the direction of change and are used in Fig. 1 as well)
(1) Reduce initiation of diverted prescription (Rx) opioids (↓Diverted Rx Init)

Programs that target children and adolescents at
risk of substance use, including prescription
opioids or heroin, with the most robust evidence
for prescription opioids (42, 43)

(2) Reduce heroin initiation with or without prior Rx use (↓Heroin Init)

Patient education on the risks of misuse (68);
disposal programs for excess pills (69)

(3) Reduce misuse initiation of own Rx opioids (↓Own Rx Init)

Prescriber education and guidelines (70); policies
to support non-opioid pain management therapies
(47)

(4) Reduce the number of people who receive an opioid Rx (↓People with Rx)

Effective treatment for mental health disorders
that are associated with risk of OUD development
(49, 71); multifaceted support during economic
crises (51)

(5) Reduce OUD development rate (↓Developing OUD)
(B) Buprenorphine treatment capacity*

Increased waiver training or modifying/removing
DATA 2000 waiver requirements (72, 73)

(6) Increase providers who can legally prescribe buprenorphine (↑Bup Providers)
†

(7) Increase buprenorphine providers’ capacity to treat more patients (↑Bup Prov Capacity)

Remove barriers to and enhance facilitators of
buprenorphine prescribing (37); policies that
target clinicians directly or enact changes to health
care structure, delivery, and payment (40)

(C) Recovery support
Remove barriers to and enhance facilitators of
improved functioning for people in remission
(74, 75)

(8) Reduce return to OUD rate from remission (↓Return to OUD)‡
(9) Add a reinforcing loop that reduces return to OUD rate as more people enter remission (↑Peer Recovery)

Peer recovery support services, mutual aid (64, 65)

(D) Overdose harm reduction
(10) Reduce excess overdose risk associated with fentanyl use (↓Fent OD Risk)

§

(11) Increase distribution of naloxone (Nx) kits to people who use opioids (↑Nx Kits)

Fentanyl test strips and other drug-checking
services (25, 76); harm reduction education on how
to adjust drug use behavior, such as titrating or
decreasing dose (26–28)
Increased naloxone kit distribution (77, 78)

*We increase buprenorphine capacity but not methadone or extended-release injectable naltrexone capacities because buprenorphine is the only MOUD with
reliable national capacity estimates.   †We modified a model-estimated parameter that abstractly accounts for provider and system constraints and, in SOURCE,
affects how many people providers can treat, on average (see section S6A). We assume that these capacity constraints are a primary cause of accessibility barriers
faced by patients.   ‡“Return to OUD” occurs after remission, where “remission” reflects the DSM-5 definition of not meeting OUD criteria for at least 1 year.
Return to OUD is sometimes referred to as relapse, but we prefer a less pejorative term.   §This excess overdose risk was estimated during model calibration. It
does not represent a change in the drug supply or a reduction in the lethality of a fentanyl overdose. We also refer to this in the text as “fentanyl harm reduction.”
Harm reduction strategies such as not using alone, which works by reducing the likelihood of fatality once an overdose has occurred, are not examples of this strategy.
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level. Prescription opioid misuse prevention interventions were the
only ones that we identified with reliable effect sizes, but these have not
been tested at a national level. Because of the lack of documented
effect sizes and varying levels of evidence across the 11 strategies, we
facilitate comparison by testing an across-the-board 20% effect size.
Twenty percent is large enough to identify effects but not so large as to
be unrealistic. We also tested the strategies at 10 and 50% effect sizes
to identify potential nonlinearities in impacts. To identify synergies,
in which the combination of strategies is greater than the sum of its
parts, we tested three packages of multiple strategies enacted simultaneously, as well as all 55 pairwise combinations of strategies.
The simulation starts in 2022, and all strategies are assumed to
come gradually into full effect over 3 years, reflecting time to implementation; they are thereafter permanent. Thus, these changes represent sustained interventions or policies, not short-term bursts of
additional resources.
Strategy analysis
We describe the effects of the 11 strategies on annual OUD prevalence and opioid overdose deaths and their effects on cumulative
person-years of OUD and cumulative opioid overdose deaths from

A Misuse and OUD prevention
(1)

Diverted Rx Init

(2)

Heroin Init

B Buprenorphine treatment capacity
(6)

Bup Providers

(7)

(3)

Own Rx Init

(4)

People with Rx

(9)

Peer Recovery

(5)

Developing OUD

C Recovery support

Bup Prov Capacity

(8)

Return to OUD

D Overdose harm reduction
(10)

Fent OD Risk

(11)

Nx Kits

Fig. 1. Annual effects of strategies. Annual fractional change and 95% credible intervals across 11 strategies evaluated within the categories of (A) misuse and OUD
prevention (five strategies), (B) buprenorphine treatment capacity (two strategies), (C) recovery support (two strategies), and (D) overdose harm reduction (two strategies). The outcomes are the prevalence of OUD (dashed blue line with blue shading for intervals) and opioid overdose deaths (solid red line with red shading for intervals)
relative to baseline (dotted horizontal line at 0%), 2022–2032.
Stringfellow et al., Sci. Adv. 8, eabm8147 (2022)
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while the examples in the table reflect many of the more commonly
discussed ways that OUD and opioid overdose could be reduced, they
are not exhaustive. Moreover, not all examples directly correspond
to their implementation in the model, and their level of evidence
varies. Because identifying high-impact targets sometimes means
thinking beyond the existing toolset, we did not limit ourselves to
strategies corresponding to existing evidence-based policies or interventions. For instance, we could not find evidence-based policies or
interventions for #5 and #8, so the corresponding hypothetical examples in Table 1 are potential interventions that target associated
risk factors such as socioeconomic status and mental illness. We
operationalized these strategies in SOURCE to directly reduce the
calibrated base transition rates, which implicitly include the influence
of factors that drive opioid use and OUD, such as social determinants
of health, trauma exposure, mental illness, genetics, and so on. These
factors’ implicit inclusion in the base rates means that we assume
that they are not part of population-level feedback loops and have
remained consistent over the model’s time horizon (1999 to 2020)
rather than varying dynamically.
Even existing interventions or policies rarely have reliably documented effect sizes, let alone effect sizes readily translated to a national
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of the recovery support strategies in later years relative to baseline.
Last, the overdose harm reduction strategies (Fig. 1D, 10 and 11)
lead to a slight increase in OUD prevalence (+1.6% and +0.3%,
respectively) because of lives saved. For more discussion about the
interaction between changes in OUD and the prescription opioid
availability balancing loop, and how this interaction changes the
annual effects of the strategies, see section S9B.
Effects of strategies on annual opioid overdose deaths
Prescription opioid misuse prevention strategies have small annual
effects on opioid overdose deaths through 2032, whether targeting
people at risk of misusing with diverted prescriptions (−0.4%; Fig. 1A,
1) or with their own prescription (−0.1%; Fig. 1A, 3).
Reducing heroin initiation (Fig. 1A, 2), the number of people
receiving a prescription (Fig. 1A, 4), and the rate of development of
OUD Fig. 1A, 5) have roughly equivalent effects on overdose deaths.
None of these strategies achieves more than 2% reductions by 2032;
however, as with OUD, their preventative nature means that their
impacts grow over time.
In contrast to the other prevention strategies, reducing heroin initiation has a greater impact on overdose deaths than on OUD prevalence. Even new initiates to heroin use are at risk of fentanyl exposure
and hence immediately experience higher overdose risk, whereas there
is a delay before they develop OUD. Therefore, reducing heroin initiation has a more immediate and disproportionate impact on overdose deaths than reducing prescription opioid initiation has.
Increasing the number of buprenorphine providers does not reduce overdose deaths in the near or long term (Fig. 1B, 6). Growing
buprenorphine providers’ capacity to treat more people (Fig. 1B, 7),
on the other hand, has among the largest effects on opioid overdose
deaths in the near term, reaching a peak annual reduction of approximately 2% by mid-2023 before falling quickly to having no
impact relative to baseline. After mid-2023, we project that capacity
limitations will ease due to less demand for treatment arising from
continued decreases in OUD involving heroin. The large uncertainty
around the effect of buprenorphine capacity on opioid overdose
deaths, as reflected in the shading in Fig. 1B, 7, is due to uncertainty
about how quickly OUD involving heroin will fall.
By 2032, the two recovery support strategies have among the largest
effects on lives saved: 5.7% for the reduction in the return to OUD
rate (Fig. 1C, 8) and 6.1% for the peer recovery loop (Fig. 1C, 9). The
recovery support strategies have such a large effect because they keep
people in remission who otherwise would have returned to OUD,
reducing the number of people at risk of overdose relative to baseline.
Similar to the effects on OUD prevalence, the peer recovery loop is
slightly stronger than reducing the rate of return to OUD. The impact of both strategies relative to baseline wanes over time.
The fentanyl harm reduction strategy (Fig. 1D, 10) and increasing naloxone distribution to people who use opioids (Fig. 1D, 11)
have the largest and most immediate annual effects on opioid overdose
deaths, peaking at reductions of 14.2% for fentanyl harm reduction
and 3.4% for naloxone kits, both in 2025. The harm reduction strategies’ impacts do not grow after the 3-year implementation ends
because they do not affect the underlying structure of the system,
i.e., they do not affect developing or remitting from OUD.
The fentanyl harm reduction strategy and the two recovery support strategies appear to surpass the effects of naloxone kit distribution by 2032. However, the implementation of these strategies in
SOURCE is not directly comparable. The availability of relevant
data (see table S2) and decades of research on naloxone, including
4 of 14
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2022 to 2032. We end by analyzing combinations of strategies and
the impacts of strategies at 10 and 50% compared to the main results tested at 20%. Figure 1 shows the effects of the 11 strategies on
annual opioid overdose deaths and OUD from 2022 to 2032 with
95% credible intervals (also see S2) relative to the baseline scenario.
Effects of strategies on annual OUD prevalence
The annual effects of reducing opioid initiation on OUD prevalence
(Fig. 1A, 1 to and 3) are minor, regardless of strategy (with a maximum reduction of 0.8% for diverted misuse, 0.4% for heroin, and
0.3% for own prescription misuse by 2032). However, their effects
grow over time because the impact of misuse prevention interventions on OUD takes years to manifest.
Decreasing the number of people who receive an opioid prescription (Fig. 1A, 4) has a larger effect on OUD prevalence (−3.7%)
than does a reduction in OUD development rates (−2.4%) as of 2032
(Fig. 1A, 5). This is because reducing the prescribing rate has multiple
channels of effect in SOURCE by limiting the volume of prescription opioids in circulation. Specifically, in SOURCE, reducing prescribing reduces misuse initiation by reducing patients receiving
opioids and among those who would use diverted opioids. It also
reduces OUD development and increases the rate at which people
quit misusing prescription opioids (because they are harder to obtain).
The reduction in OUD achieved through opioid prescribing reductions is almost entirely in OUD involving prescription opioids.
The effect of reducing opioid prescribing on OUD involving heroin
exhibits a worse-before-better dynamic. At first, it increases slightly
compared to baseline because reducing prescription opioid availability leads some people to switch to heroin, who then subsequently
develop an OUD involving heroin. However, starting around 2028,
OUD involving heroin falls compared to baseline because the lower
prevalence of OUD involving prescription opioids reduces the population at risk of switching to heroin.
Increasing the number of buprenorphine providers does not affect
OUD prevalence (Fig. 1B, 6). However, growing buprenorphine providers’ capacity by increasing the average number of patients they
can treat does reduce OUD prevalence in the short term (Fig. 1B, 7),
although the effects are small (achieving no more than a 0.44% reduction, in 2023, before falling to 0%). The effects are short term because
increasing buprenorphine providers’ capacity is helpful only when
capacity would otherwise not be able to meet demand. We project
that, by 2024, buprenorphine capacity will be able to meet demand
in the baseline scenario due to the projected declining prevalence of
OUD, especially that involving heroin. We estimate that a 20% increase
in capacity would translate to providers treating, on average, nearly
seven patients at a time compared to five in the baseline by 2025.
The recovery support strategies (Fig. 1C, 8 and 9) are the most
impactful in reducing OUD prevalence by 2032 (−5.2% for return
to OUD and −5.4% for peer recovery). We project that people returning to OUD after at least a year of remission (i.e., “relapse”) will
be an increasingly larger source of OUD prevalence compared to
incident OUD. Thus, reducing the return to OUD rate has greater
effects on OUD than reducing misuse initiation and OUD development have. The peer recovery loop has an even larger impact than
the direct reduction in the return to OUD rate because of the loop’s
reinforcing nature. Over time, as more people are in remission, the
reduction in the return to OUD rates grows, keeping even more
people in remission. (Conversely, as fewer people are in remission,
the magnitude of the rate reduction diminishes.) As OUD declines
in the baseline model, remission rates also fall, reducing the impact
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% Change in projected cumulative
person-years of OUD

1%

least a 0.5% reduction in either cumulative person-years of OUD or
opioid overdose deaths from 2022 to 2032 (i.e., strategies #2, 4, 5, 8,
9, 10, and 11 in Table 1). We show the annual effects of these packages in Fig. 3, while the cumulative effects are shown in fig. S4.
Package 1 (Fig. 3A and fig. S4, “package 1”) was the most effective
package identified annually and cumulatively. It achieved a maximum
annual reduction of 29.9% in opioid overdose deaths and 15.1% in
OUD prevalence in 2032, while, cumulatively, the reduction was
21.7% in overdose deaths and 7.3% in person-years of OUD. However, these effects are additive, meaning there were no synergistic
impacts (i.e., multiplicative effects). The large initial reduction in
opioid overdose deaths in package 1 is due to the inclusion of the
fentanyl harm reduction strategy.
Package 2 (Fig. 3B and fig. S4) included the same strategies as
package 1, except that we removed the fentanyl harm reduction
strategy (#10 in Table 1). Removing the fentanyl harm reduction
strategy means that package 2 achieves much smaller annual and
cumulative reductions in opioid overdose deaths by 2032 (a maximum
of 19.1% annually in 2032 and 11.8% cumulatively) than package 1.
These reductions are only slightly larger than the reductions from the
fentanyl harm reduction strategy alone (14.2% peak annual reduction in 2025 and a cumulative reduction of 11.3%). The OUD annual
reduction as of 2032 is slightly larger relative to baseline (16.3% compared to 15.1%) due to more people with OUD dying absent the
fentanyl harm reduction strategy. This package is also additive.
The relative impact comparison between packages 1 and 2 is
sensitive to assumptions about the future growth of fentanyl (see
section S9D and fig. S7). If fentanyl penetration does not grow
beyond its estimated 2020 level of 56% of the heroin supply, the
cumulative effect of fentanyl harm reduction is only 9%. If we assume
that fentanyl penetration reaches 100% by 2032, the fentanyl risk
reduction strategy reduces cumulative overdose deaths by 12.8%, surpassing the effects of the six other strategies combined (package 2)
(see fig. S8).
Last, given the ongoing interest in expanding buprenorphine
capacity, we tested a slightly different package of seven strategies

Fent OD
Risk

Bup
Providers
Bup Prov
Capacity

Nx Kits

0%

Own
Rx Init

Heroin
Init

Diverted
Rx Init

Developing
OUD

-1%

People
with Rx

-2%

Return to
OUD

-3%
-4%
-12%

Baseline (0,0)

Peer
Recovery

-10%

-8%

-6%

-4%

-2%

0%

% Change in projected cumulative opioid overdose deaths
Fig. 2. Cumulative effects of strategies. This figure shows effects on cumulative percentage reduction of opioid overdose deaths and person-years of OUD relative to
baseline projections in 2032. The results for 11 strategies span four categories: prevention of misuse and OUD (orange circles), buprenorphine capacity (blue diamonds),
recovery supports (green triangles), and harm reduction (purple squares). The x axis shows the fractional change in cumulative overdose deaths, while the y axis shows
the fractional change in cumulative person-years of OUD relative to the baseline scenario.
Stringfellow et al., Sci. Adv. 8, eabm8147 (2022)
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inefficiencies in distribution, supported a more realistic test of the
effects of increasing its distribution (see section S6D). Thus, a
20% increase in naloxone distribution in SOURCE equates to an
approximately 10% increase in naloxone actually being administered
in the event of an overdose. Similar data and background research
are not available for the fentanyl harm reduction and recovery support strategies, which correspond to many potential interventions
with various levels of (not necessarily known or well-documented)
efficiency and efficacy.
Effects of strategies on cumulative person-years of OUD
and opioid overdose deaths
Figure 2 shows the cumulative effects, from 2022 to 2032, of implementing the 11 strategies on OUD person-years and fatal opioid
overdoses. Compared to the baseline scenario (point [0, 0]), strategies toward the bottom left achieve larger reductions in cumulative
person-years of OUD and opioid overdose deaths. See table S7 for
the cumulative opioid overdoses and person-years of OUD for
baseline and each strategy tested.
All 11 strategies have rather small effects on cumulative person-
years of OUD—no more than a 3% reduction. The greatest effect,
from peer recovery (−2.9%), translates to about 850,000 fewer
person-years of OUD (of more than 28.9 million cumulative
person-years) compared to baseline. The fentanyl harm reduction
strategy (“Fent OD Risk”) reduces cumulative overdose deaths by
11.3% (more than 61,000 lives saved), whereas every other strategy
reduces cumulative deaths by less than 4%.
An unintended consequence of overdose harm reduction strategies is a small (<0.7% total) increase in person-years of OUD due to
fewer people dying, which is offset when combined with other strategies. Moreover, even with the increased person-years of OUD, the
overdose harm reduction strategies still lead to fewer people dying
of overdose compared to baseline.
Effects of combinations of strategies on cumulative person-years
of OUD and opioid overdose deaths
We tested three examples of combinations of strategies (“packages”),
including a combination of the seven strategies that produced at

SCIENCE ADVANCES | RESEARCH ARTICLE
A Package 1

(strategies 2, 4, 5, 8, 9, 10, 11)

B Package 2

(strategies 2, 4, 5, 8, 9, 11)

C Package 3

(strategies 4-7 and 9-11)

Fig. 3. Annual change from combined strategies, or “packages.” This figure plots annual fractional change and 95% credible intervals across three packages of combined strategies in people with OUD (dashed blue line with blue shading for intervals) and opioid overdose deaths (solid red line with red shading for intervals) relative
to baseline (dotted horizontal line at 0%), 2022–2032.
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DISCUSSION

This simulation analysis sought to identify which strategies targeting opioid use and opioid overdose could save lives and reduce
OUD. We found that fentanyl harm reduction, increased naloxone
distribution, recovery support, and—if implemented quickly—
increasing buprenorphine providers’ capacity had the largest impacts
on reducing opioid overdose deaths, with modest effects on reducing OUD.
Our analysis, coupled with syntheses of the available literature
and expert opinions [e.g., (18)], can inform what may be needed to
achieve our projected reductions in opioid overdose deaths and
OUD. The feasibility, time scale, and cost of achieving a 10, 20, or
50% change vary widely across the strategies tested. In addition,
strategies differ in the strength of evidence for their benefit and the
externalities and potential unintended consequences. With those
nuances in mind, we offer some illustrative examples of the types of
interventions that correspond to the higher-impact strategies identified in SOURCE. Our intent is also to provoke readers to think
more expansively, beyond existing interventions and policies, about
how to reduce overdoses, overdose deaths, and OUD.
Fentanyl and other synthetic opioids are playing an unprecedented
role in overdose deaths, implicated in at least 67,000 fatal overdoses
during the 12 months ending November 2021, a 21% increase compared to the previous 12-month period (6). In our analysis, increased
naloxone distribution (which SOURCE assumes goes primarily to
people who use opioids) reduced fatal opioid overdoses. This finding is consistent with other models (13–17) and empirical evidence
that naloxone saves lives when made widely and freely available to
people who use opioids (19). Our analysis points additionally to the
importance of addressing naloxone distribution inefficiencies. In
SOURCE, increasing naloxone distribution by 20% led to only a
10% increase in the probability of naloxone administration in the
event of an overdose. Lowering the practical and logistical barriers
to carrying naloxone (20) could save additional lives. Regions with
low saturation would benefit the most (21). The source of naloxone
matters, too: Recent modeling analysis suggests that pharmacy
standing order- and community-based naloxone distributions are
more efficient channels than provider-based distribution (22).
Our modeling analysis is the first to show that lives could be
saved if people who use fentanyl (knowingly and willingly or not)
had evidence-based strategies to reduce their overdose risk. That is,
we shifted the intervention point from reducing the risk of death via
6 of 14
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(“package 3,” strategies 4 to 7 and 9 to 11 in Table 1 and Fig. 3C) that
included buprenorphine capacity strategies, although their cumulative impacts were smaller. In addition, we removed the strategies
that reduced the rate of heroin initiation (because it had among the
smaller effects of the original seven included strategies) and the rate of
return to OUD (because its mechanistic impact was redundant with
and slightly weaker than the peer recovery loop). All other strategies
remained, including the fentanyl harm reduction strategy. Package 3
achieved a maximum annual reduction in 2032 of 23.7% in opioid
overdose deaths and 9.3% in OUD, and cumulative reductions of 18.5%
in overdose deaths and 4.5% in OUD person-years (package 3; fig. S4).
Fentanyl harm reduction again contributed to a large initial reduction
in opioid overdose deaths, and this package was also additive.
We conducted an additional pairwise analysis (55 paired strategies), still finding no synergies. Note that a combination of all
11 strategies did not perform much better than our package 1,
achieving a maximum annual reduction in opioid overdose deaths
of 30.2%, and a 15.8% reduction in OUD prevalence, in 2032.
Cumulative reductions were 22.1% for overdose deaths and 7.7% for
person-years of OUD.
The packages presented above are only examples of the more
than 2000 possible combinations of strategies that could be tested.
However, in our exploratory testing of other combinations of strategies, we have yet to identify any synergies. Thus, to approximate
the combined impact of any of the strategies presented here, their
individual effects can simply be added.
Effects of strategies tested at 10 and 50% on cumulative
person-years of OUD and opioid overdose deaths
To identify potential nonlinear effects on outcomes of effect sizes other
than 20%, we also tested effect sizes of 10 and 50%, examining the impact
on cumulative opioid overdose deaths and person-years of OUD by
2032 (see figs. S5 and S6). For most strategies, the effects of 10 and 50%
reductions in the initiation rates were proportionate for both outcomes,
i.e., approximately 0.5× and 2.5× the effect of a 20% change, respectively.
Some strategies had nonlinear effects, although none was large.
Increasing buprenorphine provider capacity failed to reach proportional reductions in overdose deaths at a 10% effect size. Both
recovery support strategies show greater proportional reductions at
10% for both outcomes.
We only report those strategies with disproportionate outcomes
at 10% effect sizes because it is a more realistic effect size than 50%.
Results for 50% effect sizes are described in section S9C.
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buprenorphine, estimating large fatal overdose reductions (13–17).
However, these models did not include capacity limitations, which are
important to account for because buprenorphine providers would
currently be unlikely to meet the level of increased demand tested in
many models. Providers’ inability to treat more patients is a primary
reason treatment is inaccessible (34–36). Our analysis, therefore,
focused on whether increasing buprenorphine capacity would allow more people to receive treatment, thereby reducing fatal opioid
overdose and OUD prevalence. Our capacity strategy is therefore
distinct from assessing whether increased treatment receipt would
save lives; as noted above, empirical evidence and prior modeling
suggest that it would.
We found that increasing the number of providers who can prescribe buprenorphine, which might be accomplished either through
increased waiver training or by doing away with the waiver requirements altogether, has almost no effect on OUD or overdoses. This
result is consistent with empirical research, which reports several
barriers that are more prohibitive than the waiver requirement (37).
As a result, a full one-half of providers who have obtained waivers
to prescribe buprenorphine do not prescribe at all (38), and only a
small minority (~5%) write half of the buprenorphine prescriptions
(39). In contrast, increasing how many patients, on average, existing buprenorphine providers treat has one of the largest immediate
effects on reducing mortality. However, this strategy only saved lives
(relative to baseline) if implemented near term because of projected
declines in OUD, which led to easing demand on capacity. Some
policies that could achieve effects sooner rather than later include
enforcing existing parity laws and increasing reimbursement (40),
which could lead more providers to accept Medicaid insurance (18),
thereby reducing a considerable affordability barrier faced by patients
(36). Moreover, this strategy showed diminishing returns at a 10%
effect size. Any efforts undertaken will need to increase capacity
closer to the 20% effect size, translating to about two more patients
on average per provider (at any given time), from five to seven.
Our finding regarding the short-term benefit of capacity increases
holds if average treatment duration, i.e., retention, does not increase.
However, retention is a key predictor of sustained abstinence (30),
and improving retention is a primary goal of the National Institutes
of Health’s Helping to End Addiction Long-term (HEAL) Initiative (41).
If average duration were to increase, meaning providers are treating
patients for longer periods, then this would reduce their ability to
bring in new patients. Even if there is no legal limit on how many
patients providers can treat, there are only so many patients that
they are logistically capable of treating. Thus, in the event of improvements in retention, supporting providers to increase their
capacity will remain important even if OUD continues to fall.
Addressing any of the myriad barriers that providers face could
support buprenorphine prescribers to reach more patients. These
barriers include a lack of psychosocial support and services for
people with complex health and mental health conditions; limited
knowledge, education, and confidence in treating OUD; low patient
demand; stigma; and insufficient time and reimbursement (37).
We tested five misuse and OUD prevention strategies that proved
to have negligible effects on both OUD prevalence and fatal opioid
overdose, partly due to the time horizon of SOURCE’s projections.
Strategies that might have had larger impacts earlier, such as preventing initiation of opioid misuse, are now projected to have
little impact in the near term because these major population shifts
have already occurred. However, we project an increase in opioid
7 of 14
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naloxone to reducing the risk of overdose. Drug-checking interventions that detect fentanyl have received greater attention recently.
These could be useful insofar as they inform people of what they do
not already know, thus allowing them to make more informed decisions about their drug use. Drug checking includes point-of-use
fentanyl test strips (23) and higher-tech tools, such as spectrometry
and spectroscopy, that community programs can use to detect the
presence, and sometimes quantity, of fentanyl and its analogs (24).
Which tool is most useful depends partly on how recently fentanyl
has entered the local drug supply. In areas where fentanyl is already
ubiquitous, and its presence assumed, alerting people who use opioids
to the presence of potent fentanyl analogs in the local supply could
be more useful than fentanyl test strips at point of use.
For drug-checking interventions to have the greatest impact,
people must have the tools to change their drug use behavior, and
those altered behaviors should reliably reduce the risk of overdose.
Using less of the drug, using more slowly, and using a less risky
mode of administration are common harm reduction behaviors
when fentanyl’s presence in drugs is known or suspected (25–27).
However, there is room for improvement; more than half of PWUD
do not engage in these fentanyl harm reduction practices (25, 28).
Moreover, some harm reduction behaviors are likely more effective
than others at reducing overdose risk. Thus, whether drug-checking
services and associated harm reduction behaviors can achieve the
effect size modeled in SOURCE is not yet clear. Rather, our results
should be interpreted as the number of lives that could be saved if
people who use fentanyl could reduce their risk of overdose reliably.
Further resource investment in learning how to achieve such risk
reduction is a strategy worth pursuing.
Our simulations showed that two recovery support strategies had
the largest and most sustained effects on reduced OUD and thus
also on reduced opioid overdose deaths. Furthermore, these were
the only strategies that showed disproportionately positive returns
at 10% effect sizes compared to 20%, suggesting that even small improvements in recovery support represent potential leverage points.
We project that return to OUD after remission will increasingly become the primary source of OUD prevalence rather than incident
OUD. Thus, to reduce overdose deaths, it is critical to keep people
in remission, including those who have not received MOUD treatment or any treatment.
Policies and interventions that could keep people in remission
(i.e., reduce the return to OUD rate) include removing obstacles to
full reintegration into society, such as employment supports (29).
Other policies would support people to maintain improvements in
social role functioning, which is a predictor of sustained abstinence
(30). Existing interventions such as mutual aid, peer recovery support services, and recovery homes correspond most closely to the
peer recovery loop. However, to achieve the effect sizes we tested,
more research is needed to identify the most effective among these
interventions—or identify new ones. Moreover, our strategy test drew
on the 3+ million people in recovery from OUD (31), suggesting
that many more will need to be engaged. Further research is needed
on the potential of community or national peer recovery strategies.
We also encourage further testing of recovery support in opioid
modeling analyses; ours is the first to do so, despite recovery support
being a component of the national overdose prevention strategy (29).
Buprenorphine treatment saves lives (32, 33) and is a critical tool
for reducing opioid overdoses and fatalities. Other models have
tested the effect of more people receiving treatment, including

SCIENCE ADVANCES | RESEARCH ARTICLE

Stringfellow et al., Sci. Adv. 8, eabm8147 (2022)

24 June 2022

of “misuse”) is critical to more effectively intervene and a more detailed representation of OUD prevention in SOURCE.
Our modeling analysis has several limitations. First, while SOURCE
includes all overdose deaths involving opioids, including those that
also had methamphetamine or cocaine present or were due to
counterfeit pills, it does not explicitly track those or the broader category of polysubstance use. Strategies may affect polysubstance use
or overdose differently, and our analysis may miss those interaction
effects. Second, although we included 2020 data, which we assume reflected some of the effects of the coronavirus disease 2019 (COVID-19)
pandemic, we underestimated the number of deaths that occurred
in 2020, suggesting that there are additional effects not yet included.
Third, many data gaps in the OUD literature make building any
opioid model challenging (e.g., comprehensive national data on
naloxone do not exist) (52). Longitudinal natural history studies
that follow a nationally representative group of people with OUD
in and out of treatment and remission lasting at least 1 year would
be especially useful for improving transition rate estimates once
people have developed OUD.
Fourth, the opioid crisis is driven by many factors that we have
not explicitly included in SOURCE, including socioeconomic status
and other social determinants of health, trauma exposure and mental
illness, and involvement in the criminal legal system (53). Their
effects on transitions are poorly measured in the literature, so they
are implicitly reflected in the estimated baseline transition rates rather
than being separately estimated. These factors’ implicit inclusion limits
our ability to test the effects of intervening on these factors. Absent
this mechanistic detail, we allude to these factors as potential intervention points where evidence suggests that they are particularly
relevant. Our future research will engage PWUD and their communities more directly in model development. We anticipate that this
will lead to models focusing on the root causes of addiction and will
likely be more qualitative than SOURCE. These new efforts will
complement the insight gained from SOURCE.
Fifth and last, SOURCE is a national model that, like many such
models (whether addressing opioids or almost any other nationwide
phenomenon), does not attempt to capture or project regional
heterogeneity. Nonetheless, questions might arise about whether the
implications of our findings could differ in some regions, states, or
locales. We offer some guidance on thinking about and using our
findings here.
Our findings hold across regions insofar as the basic structure of
SOURCE, in terms of how drug use behavior and overdose risk
evolve (e.g., social influence, risk perception, and the role of fentanyl
in driving overdoses), is consistent across the country. We know of
no evidence to suggest otherwise. Such structural similarity could
be undermined if basic population trends such as misuse initiation
and OUD prevalence were moving in different directions across the
country. However, they are moving downward across all regions
(54). Given these assumptions of structural similarity and evidence
of similar cross-regional trends, the relative impact of strategies
would remain. However, the strategic timing might shift depending
on local conditions, e.g., fentanyl penetration or buprenorphine
capacity. For example, there is substantial geographic heterogeneity
in buprenorphine access. Increasing providers in underserved areas,
which would follow the national trend over the past several years,
could have a disproportionate impact even if this approach is ineffective at the national population level. Alternatively, areas already
implementing some of the more impactful strategies might see a
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misuse initiation beginning in the late 2020s, suggesting that discussions of how to scale misuse prevention effectively will soon be
relevant again.
Prescription opioid misuse interventions—which would correspond to our tests of diverted opioid misuse initiation, not misuse
of one’s own prescription—are among the more effective interventions available. Reductions of 4% (42) to 65% (43) have been reported,
so the effect sizes that we tested—10, 20, and 50%—provide some
insight into the effects of these interventions if scaled nationally.
Prevention of heroin use, on the other hand, is understudied. We
identified one study that reported the effects of an intervention on
heroin initiation, but the follow-up was only through eighth grade
(44)—too young to gauge the impact on behavior that usually
begins much later.
Among the prevention strategies, reducing prescribing rates and
the development of OUD had the largest effects on OUD prevalence
and opioid overdose deaths. Our approach to testing prescribing
reductions was less detailed than other opioid modeling analyses.
These other analyses have found more lives saved via policy changes
such as reducing diversion or disposing of excess pills, prescription
monitoring programs, and drug rescheduling, rather than targeting
individual prescribing practices directly (14, 15, 17). In SOURCE,
the beneficial effects of reduced opioid prescribing occur primarily
via a reduction in prescription opioids available for diversion rather
than people initiating misuse with their own prescriptions. This
finding points to the need to reduce excess and unnecessary opioid
prescribing and identify strategies that can effectively address the
root causes of diversion, for example, the desire to build social capital
or supplement income (45).
Two distinct ways of reducing the number of people who receive
prescription opioids include reductions in initiating opioid prescriptions for new patients versus tapering the dosage of existing patients (i.e., deprescribing), which we do not distinguish in
SOURCE. Numerous potential harms are associated with tapering
individuals on chronic opioids, including increased risk of opioid
overdose, inadequately treated pain, and mental distress or suicidality; more rigorous studies of these effects are limited and only just
starting to emerge (46). Reducing incident prescriptions and using
alternatives to opioids for pain management in their place (47)
could reduce patients with opioid prescriptions with fewer potential
harms. The risks and benefits of opioid prescribing for chronic
and incident pain management are understudied, and long-term
tracking of patient outcomes is needed to inform prescribing
practices (18).
Ours was the first model to examine the effect of preventing the
transition from misuse to OUD, not just diverted opioid misuse
prevention as tested previously (48). We tested both, finding larger
impacts from reducing OUD development than reducing misuse
initiation on cumulative person-years of OUD and cumulative fatal
opioid overdoses. There are no formalized evidence-based interventions for reducing this transition from misuse to OUD. Clues
for where to start can be found in the literature. For instance, psychiatric disorders are prospectively associated with risk for opioid
misuse and OUD (49), and problematic opioid use is also often
associated with economic deprivation (50). Thus, strategies for reducing OUD development might include increasing access to mental
health treatment and multifaceted support during economic crises
(51). Establishing a causal relationship between mental illness or
poverty and OUD development (and not just the broader category
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reduced impact relative to our results. Thus, our results could offer
insight into preventive planning in regions that are not as far along
in the overdose crisis while highlighting for others the importance
of maintaining effective strategies.
Despite these limitations, SOURCE is the most detailed national-
level model to date that aims to address the opioid overdose crisis.
We build on other opioid-related models by combining features
from all of them, including the inclusion of 2020 data (17), the
incorporation of feedback loops (15), an analysis of misuse prevention (48), opioid prescribing reductions (13–17), and naloxone
distribution (13–17). However, we tested a broader range of strategies than reported in other modeling papers. This broad range
allowed us to identify potential leverage points for intervention
that others have not explored, including fentanyl harm reduction,
recovery support, and increases in buprenorphine capacity (as
opposed to testing the effects of treatment receipt). As a result,
we provide new insights based on a model that endogenously
replicates historical trends, using the best available data and the
combined input of more than two dozen academic, clinical, and
public health experts.

Model development
Complete information on model development is detailed elsewhere
(12). Institutional Review Board approval was not required for this
study. All data are publicly available.

Dynamic hypothesis
SOURCE is the mathematical representation of our team’s dynamic, feedback-based hypothesis about how the so-called opioid
crisis has evolved on a national level since 1999, when the model
simulation starts, through 2020, which is the last year to which
the model is currently calibrated (due to data delays). SOURCE
is a national-level model, so we use national-level data to capture
relevant trends. These trends include misuse and OUD as reported

Fig. 4. SOURCE model overview. This figure maps the model states and transitions, with feedback loops denoted. “Rx” denotes prescription opioids. Treatment states are
further separated by MOUD type: methadone maintenance treatment, buprenorphine, and extended-release injectable naltrexone. An earlier version of this figure also
appeared in (12).
Stringfellow et al., Sci. Adv. 8, eabm8147 (2022)
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MATERIALS AND METHODS

Overview of SOURCE
SOURCE is a continuous-time differential equations model (12)
developed using a system dynamics approach in which endogenous
feedbacks drive change over time (9, 10). Endogeneity refers to system behavior arising as a function of the current and historical
dynamics of the system itself rather than arising independently of
those dynamics (55). In system dynamics, these processes are referred to as feedback loops, either reinforcing—leading to exponential
growth or decay—or balancing, which limits that growth or decay.
An endogenous perspective assumes that observed behavior arises
for reasons found in the state of the system, e.g., opioid initiation is
influenced by how many people already use opioids and the consequences people are experiencing due to opioid use. Figure 4 provides
an overview of the model population groups, their transitions, and
the key factors affecting those transitions, including feedback loops
and (diverted) prescription opioid and heroin availability. Transitions
affected by feedback loops are not static over time, but instead vary
with changing population-level dynamics.
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popular drugs are, in part, due to a growing perceived risk of those
drugs, thus making other drug classes more attractive to potential
initiates. In SOURCE, once opioid overdose deaths begin to drop,
risk perception declines after a long delay, leading to greater initiation. The rapid drop in heroin initiation cannot be reproduced
without including perceived risk balancing effects (12).
The availability of prescription opioids and heroin to potential
and existing misusers also affects initiation, OUD development,
and quitting in the model (although we assume that drug availability
does not influence remission rates). Prescription opioid availability
is part of a balancing feedback loop; as more people use prescription
opioids obtained on the street, there are fewer available for others
with which to initiate or develop an OUD. Heroin price (and its
inverse, availability) is exogenous, meaning we do not attempt to
replicate these dynamics endogenously.
The relative availability of prescription opioids compared to
heroin affects heroin initiation and development of OUD involving heroin; as prescription opioids become less available relative to
heroin, heroin initiation and OUD development rise. The strength
of this effect is also determined by how much heroin availability has
already changed. Our data sources (table S2) suggest that heroin
(not to mention illicitly manufactured fentanyl) has been more
available than diverted/street-level prescription opioids for the past
several years. Thus, further reductions in prescription opioid street
availability would not be expected to have the same effect on heroin
use as would occur if heroin were less available. The feedback loops
and availability effects interact with base rates of initiation and quitting to create dynamic transition rates that vary over time—in reality, and SOURCE (12).
Last, varying levels of treatment availability affect MOUD treatment entry, as part of a balancing loop. Increasing numbers of
people in MOUD treatment leads to reduced capacity available for
new patients.
Figure 5 shows the feedback loops in a simplified visual diagram.
There are four social influence reinforcing loops (blue): as more
people misuse prescription opioids, more people initiate misuse
with diverted prescription opioids (#1); as more people have nondisordered heroin use, more people initiate heroin, either with or

Fig. 5. SOURCE feedback loops in a simplified model structure. The loop numbers shown here are referred to and discussed in the text. “Rx” denotes prescription opioids,
and “H” denotes heroin. Treatment includes methadone maintenance therapy, buprenorphine, and extended-release injectable naltrexone. An earlier version of this figure
also appeared in (12).
Stringfellow et al., Sci. Adv. 8, eabm8147 (2022)
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in the National Survey on Drug Use and Health (NSDUH) (7) and
opioid overdose deaths as reported by U.S. Centers for Disease
Control and Prevention (CDC) (1). See fig. S1, which compares
these historical data against our calibrated output (12). We correct
for NSDUH’s likely underestimation in people who use heroin (see
section S4A, iv).
We offer a brief qualitative summary of the overall trends depicted in fig, S1. In the early 2000s, there was a steady fall in prescription opioid misuse initiation and prevalence of misuse. At the
same time, OUD involving prescription opioids (“Rx OUD”) continued to rise until a peak around 2011, simultaneous with a continued
rise in opioid prescribing. During this same time (the 2000s), there
was an exponential rise in prescription opioid overdose deaths. From
2008 to 2015, heroin initiation rose rapidly, fueling a rapid rise in
people with OUD involving heroin (“HUD”) and heroin overdose
deaths. However, since 2015, there has been a marked drop in heroin
initiation, and HUD appears to have peaked in 2017. Fentanyl-
involved overdoses began to rise in 2014 and have not decreased
since. Total opioid overdose deaths appeared to be plateauing in 2017,
but 2020 (as well as provisional 2021) data show a reversal of that
trend, with the largest rise yet (6).
SOURCE is a high-level, data-driven, national epidemiological
model. Thus, it relies on a parsimonious dynamic hypothesis to
explain and then replicate through formal model estimation the
above-described trends. The model includes two competing feedback
processes, identified based on interviews and close collaboration with
subject matter experts over 2 years (see S1). These processes drive
the observed national trends in opioid initiation and therefore also
affect the national prevalence of use and use disorder: (i) social
influence, which leads more people to use opioids as others around
them increasingly use (56, 57)—or, conversely, to less initiation as
fewer people use, and (ii) risk perception, which slows initiation
and increases quitting as the perceived risk associated with opioids
use rises (but can also have the opposite effect) (58). The risk perception feedback is informed by literature, suggesting a generational
effect that drives the cyclical nature of drug “epidemics” in the United
States, i.e., the historical population-level switching between opioids
and stimulants (59, 60). This view posits that falls in the initiation of
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Model calibration
SOURCE is calibrated using 15 time-series data targets from 1999
to 2020. These data targets are incidence and prevalence data from
NSDUH, opioid overdose deaths from the CDC National Vital
Statistics System, and IQVIA data on prescriptions dispensed for
buprenorphine OUD products (table S1) (12). Model parameters were
estimated using a combination of four types of inputs: (i) exogenous historical data inputs (table S2); (ii) a set of priors to inform
treatment-, remission-, and overdose-related estimates (table S3);
(iii) literature, datasets, and expert judgment (table S4); and, where
there were no reliable data, (iv) formal estimation (table S5). All
feedback loop strengths and most base transition rates are formally
estimated to achieve the best fit to history and were constrained to
plausible ranges (see section S2 for more detail on estimation).
Historical replication is a primary form of validation in simulation modeling (61) but one too infrequently used in opioid modeling
Stringfellow et al., Sci. Adv. 8, eabm8147 (2022)
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(62). The goal with SOURCE is to replicate trends endogenously,
i.e., using the model structure itself, which is critical for making
reliable projections. Such endogenous processes will continue to play
out in the future and thus interact with policies and interventions in
complex and often unanticipated ways. SOURCE successfully replicates historically observed patterns of opioid use and overdose
mortality (12). The average R2 against data is 0.76, while mean
absolute errors normalized by mean are 12.7% (see table S6).
Baseline model and projections
In the baseline model, both OUD and fatal opioid overdoses are
projected to decline through 2032 (see fig. S2) (12), although
how soon and how quickly depends on assumptions about fentanyl’s
continued penetration of the heroin market (fig. S7). We assumed
that fentanyl penetration would continue to rise, albeit at a decelerating rate. We assumed that naloxone distribution and buprenorphine
providers would also rise and that opioid prescribing would continue
to fall, all at decelerating rates. (These are all exogenous inputs, not
the time-series data to which we calibrate.) See section S5 and table S2
for more details on data sources and section S8 for how we established plausible trends for these exogenous time series.
Rationale for and implementation of strategy testing
Opioid misuse and OUD prevention
Interventions to reduce misuse of prescription opioids or heroin
and the rate of OUD development are operationalized in SOURCE
by adjusting the base transition rates, which implicitly include important risk factors not captured in our feedback loops, including
socioeconomic status and mental illness. We operationalized a reduction in the opioid prescribing rate by adjusting downward our
base case projections, derived from IQVIA Total Patient Tracker® data,
of how many people will receive prescription opioids annually.
Buprenorphine capacity
Increased treatment engagement could occur by increasing treatment capacity. We could only find national capacity data for
buprenorphine. National capacity data are not available for methadone
maintenance treatment or extended-release injectable naltrexone
(i.e., Vivitrol), so we could not test increases in their capacity.
We assume that accessibility barriers experienced by patients are
largely the result of provider capacity limitations and systemic
barriers such as lack of public transportation and are therefore not
problems to be solved by individual patients. Hence, we discuss capacity rather than accessibility, although these are two sides of the
same coin. For instance, increasing buprenorphine capacity might
decrease wait times, thereby increasing accessibility.
We test two ways to increase buprenorphine capacity. The first is
to increase beyond base projections the number of providers who will
legally be able to prescribe buprenorphine (see section S5C). The second is to increase the average number of patients buprenorphine
providers can treat, which we call “effective capacity.” Effective capacity is operationalized in SOURCE using a model-calibrated parameter that estimates the rate of observed diminishing returns on
each additional waivered provider (see section S6A). Other patient
barriers to treatment, such as lack of affordability, are accounted for
in SOURCE but not part of our strategy testing (see section S1A, ii).
Recovery support
We test two ways of reducing the return to OUD (i.e., relapse) after
remission. We use the DSM-5 (Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition) definition of remission: at least 1 year
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without prior prescription opioid misuse (#2-3, shown together for
simplicity). Finally, the more people who have Rx OUD with nondisordered heroin use (Rx + H in the ‘opioid use disorder’ stock) or
OUD involving heroin, the more people who initiate heroin from
Rx OUD (#4). In SOURCE, all people who use prescription opioids,
including those with an OUD or who also use heroin, exert a social
influence on diverted prescription opioid misuse initiation (but not
misuse initiation with one’s own prescription, which we assume
is not socially influenced). Similarly, all people who use heroin, including those with an OUD, influence heroin initiation. For simplicity, these extra inputs are not shown in the figure.
The perceived risk loops (Fig. 5, orange) show that as opioid overdoses increase, especially fatal overdoses, risk perception does as well.
There are six perceived risk loops in SOURCE. Increasing perceived
risk leads to decreased initiation of prescription opioid misuse with
diverted prescriptions (#5), decreased initiation of heroin with or
without prior prescription opioid misuse (#6-7) or with prior prescription opioid use disorder (#8), and decreased prescription opioid
misuse initiation with own prescriptions (#9). Increasing risk perception also increases prescription opioid misuse quitting (#10).
There are five balancing feedback loops involving street availability of prescription opioids (Fig. 5, purple). Two of these operate
in tandem with an exogenous heroin availability effect; these are
only shown in Fig. 4, but not Fig. 5. The three that do not involve
heroin are the following: as the number of people with Rx OUD or
prescription opioid misuse increases, so does prescription opioid
demand and thus consumption, limiting street prescription opioid
availability for others, which then reduces misuse initiation (#11)
and OUD development (#12) and increases quitting of prescription
opioid misuse (#13). Finally, treatment availability balancing loops
(Fig. 5, green) limit treatment entry as available capacity is utilized
(#14-16, one for each OUD).
Feedback loops’ impacts vary over time and are determined by a
combination of the strength of their effect, i.e., how sensitive the
population is to them and the relative magnitude of the factors driving
them. For instance, if social influence on initiation is strong, indicating great sensitivity within the at-risk population to how many
other people are already using a given drug, then many people using
that drug will powerfully influence others to initiate. Conversely, a
small number of people using will also greatly suppress initiation if
the feedback loop is strong. A weaker feedback loop exerts less
influence, positively or negatively.
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without meeting OUD criteria, after having met OUD criteria before (63). The first strategy is a reduction in the return to OUD rate,
which is best conceptualized as any policy or set of policies that
target factors that increase the risk of relapse, such as declining
social role functioning (30). This transition in SOURCE involves people
who are no longer or never were in MOUD treatment, so it does not
correspond to interventions targeting people currently enrolled in
MOUD treatment.
The second recovery support strategy that we tested is a peer
recovery loop, where we added a new reinforcing loop (see fig. S3).
The theory of change is that people in remission can provide positive
role modeling and hopeful examples for others to maintain their
own positive changes. The peer recovery loop is operationalized such
that an increase in the number of people in remission slows the rate
of return to use disorder. We tested this loop to gauge the potential
of a strategy that harnesses reinforcing social dynamics and observe
whether it would yield different results than a simple reduction in
the return to OUD rate. Although peer recovery could include social
network effects naturally occurring without outside intervention,
the evidence was not strong enough to include it in the base model.
While self-help, mutual aid, and peer recovery support services are
somewhat efficacious in supporting abstinence (64, 65), the effect
sizes that we tested were hypothetical. To facilitate comparison, we
set the strength of this loop to achieve a 20% reduction in the return
to OUD rate as of 2025.
Overdose harm reduction
SOURCE supports testing what might happen were the likelihood
of experiencing overdose reduced, distinct from the likelihood of
naloxone administration in the event of an overdose. Thus, we tested
overdose harm reduction in two ways. The first was to reduce the
risk of overdose, specifically involving illicitly manufactured fentanyl
(Fent OD Risk in Table 1, which we also refer to as the fentanyl
harm reduction strategy). The second was to reduce fatality in the
event of an overdose by testing the effects of an increase in naloxone
kit distribution beyond baseline assumed increases.
Our decision to test the risk of overdose involving illicitly manufactured fentanyl assumes that (i) fentanyl will continue to be present
in the heroin supply, and increasingly so (66); (ii) people who use
opioids, as well as other drugs, will be increasingly likely to use fentanyl,
willingly or not (67); (iii) many people will decide to use the drugs
they have purchased, even if they know or suspect fentanyl’s presence
(28); and (iv) fentanyl’s presence in the drug supply and its inherent
lethality are less amenable to sustainable intervention than changing
the behavior of people who use fentanyl so that they are less likely to
experience overdose in the first place (i.e., through drug-checking
services and associated harm reduction behaviors).
We did not identify any national-level estimates of the availability of drug-checking services. We also did not identify the effect
sizes of various other harm reduction strategies, such as titration, on
reducing the likelihood of overdose. Therefore, the fentanyl harm
reduction strategy is operationalized as a direct reduction in the
excess overdose risk associated with fentanyl relative to heroin. In
contrast, the naloxone kit distribution strategy is operationalized as
an increase in the number of kits distributed, which was possible
because we have historical estimates of naloxone distribution via
harm reduction programs and prescription channels (table S2 and
section S5D). In addition, prior research on the efficiency of distribution [e.g., (22)] supported estimating an efficiency parameter
(section S6D).
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